Abstract
Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Volume: 13 Issue: 2
Author(s): Wilbert S. Aronow
Affiliation:
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Abstract: Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Export Options
About this article
Cite this article as:
Aronow S. Wilbert, Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1871529X11313020008
DOI https://dx.doi.org/10.2174/1871529X11313020008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Hydroxyimine NO-Donors; FK409 and Derivatives
Current Topics in Medicinal Chemistry Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Cardiac Telocytes
Current Stem Cell Research & Therapy Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?
Current Vascular Pharmacology Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis
Current Pharmaceutical Design When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical Design CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism Exploiting Anti-Inflammation Effects of Flavonoids in Chronic Inflammatory Diseases
Current Pharmaceutical Design Cardioprotective Effects of Serca2a Overexpression Against Ischemiareperfusion- induced Injuries in Rats
Current Gene Therapy Mesenchymal Stem Cells for Ischemic Stroke: Progress and Possibilities
Current Medicinal Chemistry Ivabradine: a Selective If Current Inhibitor in the Treatment of Stable Angina
Recent Patents on Cardiovascular Drug Discovery A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry